Chitinase 3-like 1: Prognostic biomarker in clinically isolated syndromes

Brain

Volumn 138, Issue 4, 2015, Pages 918-931

  Canto, Ester ^a   Tintore, Mar ^a   Villar, Luisa M ^b   Costa, Carme ^a   Nurtdinov, Ramil ^a   Alvarez Cermeno, José C ^b   Arrambide, Georgina ^a   Reverter, Ferran ^c   Deisenhammer, Florian ^d   Hegen, Harald ^d   Khademi, Mohsen ^e   Olsson, Tomas ^e   Tumani, Hayrettin ^f   Rodriguez Martin, Eulalia ^b   Piehl, Fredrik ^e   Bartos, Ales ^g   Zimova, Denisa ^g   Kotoucova, Jolana ^g   Kuhle, Jens ^h   Kappos, Ludwig ^h   Garcia Merino, Juan Antonio ⁱ   Sánchez, Antonio José ⁱ   Saiz, Albert ^c   Blanco, Yolanda ^c   Hintzen, Rogier ^j   Jafari, Naghmeh ^j   Brassat, David ^k   Lauda, Florian ^f   Roesler, Romy ^f   Rejdak, Konrad ^l,m   Papuc, Ewa ^l   De Andrés, Clara ⁿ   Rauch, Stefan ^d   Khalil, Michael ^o   Enzinger, Christian ^o   Galimberti, Daniela ^p   Scarpini, Elio ^p   Teunissen, Charlotte ^q   Sánchez, Alex ^c,r   Rovira, Alex ^a   Montalban, Xavier ^a   Comabella, Manuel ^a   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF ULM   (Germany)

^g CHARLES UNIVERSITY   (Czech Republic)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k University of Toulouse III   (France)

^l MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^m MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o MEDICAL UNIVERSITY OF GRAZ   (Austria)

^p UNIVERSITY OF MILAN   (Italy)

^q VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^r Institut de Recerca   (Spain)

more..

Author keywords

biomarker; clinically isolated syndrome; disability progression; multiple sclerosis

Indexed keywords

CHITINASE; CHITINASE 3 LIKE 1; OLIGOCLONAL BAND; UNCLASSIFIED DRUG; ADIPOCYTOKINE; BIOLOGICAL MARKER; CHI3L1 PROTEIN, HUMAN; LECTIN;

ADULT; AGED; ARTICLE; ASTROCYTE; BRAIN TISSUE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MONOCYTE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK FACTOR; BIOSYNTHESIS; BRAIN; CLINICAL TRIAL; DEMYELINATING DISEASES; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN; DEMYELINATING DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LECTINS; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84929095477     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv017     Document Type: Article

References (52)

1. Badariotti F, Kypriotou M, Lelong C, Dubos MP, Renard E, Galera P, et al. The phylogenetically conserved molluscan chitinase-like protein 1 (Cg-Clp1), homologue of human HC-gp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes. J Biol Chem 2006; 281: 29583-96.
2. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11): 2059-69.
3. Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, et al. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 2009; 40: 1790-7.
4. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006; 281: 21082-95.
5. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibro-blast growth factor. Am J Pathol 2008; 173: 130-43.
6. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010; 7: 34.
7. Boot RG, Blommaart EF, Swart E, Ghauharali-van der Vlugt K, Bijl N, Moe C, et al. Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 2001; 276: 6770-8.
8. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006; 66: 503-13.
9. Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J Neurol 2005; 252: 1067-73.
10. Canto E, Reverter F, Morcillo-Suarez C, Matesanz F, Fernandez O, Izquierdo G, et al. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler 2012; 18: 983-90.
11. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999; 79: 1494-9.
12. Comabella M, Fernandez M, Martin R, Rivera-Vallve S, Borras E, Chiva C, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-93.
13. Correale J, Fiol M. Chitinase effects on immune cell response in neu-romyelitis optica and multiple sclerosis. Mult Scler 2011; 17: 521-31.
14. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010; 68: 903-12.
15. Choi J, Lee HW, Suk K. Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease. J Neurol 2011; 258: 2181-5.
16. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007; 357: 2016-27.
17. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004; 22: 3330-9.
18. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-17.
19. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
20. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803-10.
21. Hempen M, Kopp HP, Elhenicky M, Hobaus C, Brix JM, Koppensteiner R, et al. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 2009; 19: 1557-63.
22. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 2011; 13: 1244-51.
23. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003; 9: 4423-34.
24. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32: 911-20.
25. Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis-A potential marker of disease activity? Respir Med 2005; 99: 396-402.
26. Kzhyshkowska J, Gratchev A, Goerdt S. Human chitinases and chit-inase-like proteins as indicators for inflammation and cancer. Biomark Insights 2007; 2: 128-46.
27. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977; 37: 397-401.
28. Louboutin JP, Chekmasova A, Marusich E, Agrawal L, Strayer DS. Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage. FASEB J 2011; 25: 737-53.
29. Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-Sorensen K, et al. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 2010; 211: 589-95.
30. Ostergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 2002; 9: 598-604.
31. Park HY, Jun CD, Jeon SJ, Choi SS, Kim HR, Choi DB, et al. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 2012; 7: e51722.
32. Park JA, Drazen JM, Tschumperlin DJ. The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. J Biol Chem 2010; 285: 29817-25.
33. Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 2001; 20: 192-6.
34. Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010; 38: 1448-57.
35. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011; 6: e16032.
36. Persson F, Rathcke CN, Gall MA, Parving HH, Vestergaard H, Rossing P. High YKL-40 levels predict mortality in patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 96: 84-9.
37. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-6.
38. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
39. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chiti-nase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221-5.
40. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998; 251: 504-9.
41. Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JM. Purification and characterization of human chitotriosi-dase, a novel member of the chitinase family of proteins. J Biol Chem 1995; 270: 2198-202.
42. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012; 64: 671-7.
43. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995; 270: 13076-83.
44. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172: 4410-7.
45. Teunissen C, Menge T, Altintas A, Alvarez-Cermeno JC, Bertolotto A, Berven FS, et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013; 19: 1802-9.
46. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-22.
47. Thom I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010; 116: 4114-21.
48. Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-72.
49. Tintore M, Rovira A, Rio J, Tur C, Pelayo R, Nos C, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70: 1079-83.
50. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 599-605.
51. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110: 351-60.
52. Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2000; 59: 544-8.